According to Auriga, the new product combines one of the most frequently prescribed drug classes for this condition, in a unique dosage form previously not available.
The product is expected to be approved by the FDA in early 2008 and launched during the second quarter of 2008.
Philip Pesin, CEO of Auriga, said: “This agreement solidifies Auriga’s commitment to enhance our product portfolio with products approved using the ANDA and 505(b)(2) NDA regulatory pathways.”